NCT06360042View on ClinicalTrials.gov

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Adebrelimab plus Apatinib

Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily

DRUG

Adebrelimab plus Bevacizumab

Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks

DRUG

Camrelizumab plus Apatinib

camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER